Open Access Articles- Top Results for Besonprodil


Systematic (IUPAC) name
Clinical data
253450-09-8 7pxN
PubChem CID 156328
ChemSpider 137662 7pxY
UNII 5K3N2D15WW 7pxY
ChEMBL CHEMBL219631 7pxY
Synonyms Besonprodil, CI-1041
Chemical data
Formula C21H23FN2O3S
402.481 g/mol
 14pxN (what is this?)  (verify)

Besonprodil (CI-1041) is a drug which acts as an NMDA antagonist, selective for the NR2B subunit.[1][2] It is under development as a supplemental medication for Parkinson's disease, and has been shown in animals to be effective in counteracting the dyskinesias associated with long term treatment with levodopa and related drugs.[3][4][5][6][7]


  1. ^ Kovács G, Kocsis P, Tarnawa I, Horváth C, Szombathelyi Z, Farkas S (January 2004). "NR2B containing NMDA receptor dependent windup of single spinal neurons". Neuropharmacology 46 (1): 23–30. PMID 14654094. doi:10.1016/S0028-3908(03)00339-3. 
  2. ^ Barton ME, White HS (March 2004). "The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression". Epilepsy Research 59 (1): 1–12. PMID 15135162. doi:10.1016/j.eplepsyres.2003.12.010. 
  3. ^ Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T (January 2006). "Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin". Movement Disorders : Official Journal of the Movement Disorder Society 21 (1): 9–17. PMID 16127720. doi:10.1002/mds.20654. 
  4. ^ Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T (September 2006). "Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors". Synapse (New York, N.Y.) 60 (3): 239–50. PMID 16739115. doi:10.1002/syn.20295. 
  5. ^ Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Grégoire L, Meltzer LT, Di Paolo T (June 2009). "Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias". Journal of Molecular Neuroscience : MN 38 (2): 128–42. PMID 18704766. doi:10.1007/s12031-008-9137-8. 
  6. ^ Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T (January 2010). "Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides". Neuropharmacology 58 (1): 286–96. PMID 19576910. doi:10.1016/j.neuropharm.2009.06.030. 
  7. ^ Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T (June 2010). "Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias". Neuroscience 167 (4): 1160–7. PMID 20303391. doi:10.1016/j.neuroscience.2010.03.022. 

Template:Glutamate receptor ligands

Lua error in package.lua at line 80: module 'Module:Buffer' not found.